Uniphar (LON:UPR) Hits New 1-Year High - What's Next?

Key Points

• Uniphar plc's shares reached a new 52-week high of GBX 346.02 ($4.59) recently, indicating strong stock performance with a trading volume of 32,442 shares.
• Analysts have given mixed ratings, with Shore Capital maintaining a "buy" rating, while Deutsche Bank set a price target of GBX 375 ($4.97) with a "hold" recommendation.
• Uniphar has a market capitalization of £1.08 billion, a PE ratio of 24.06, and operates across various healthcare divisions, employing over 2,000 people.

Uniphar plc (LON:UPR - Get Free Report)'s share price reached a new 52-week high on Thursday . The stock traded as high as GBX 346.02 ($4.59) and last traded at GBX 346.02 ($4.59), with a volume of 32442 shares trading hands. The stock had previously closed at GBX 336 ($4.46).

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on UPR shares. Shore Capital reissued a "buy" rating on shares of Uniphar in a research note on Thursday, May 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a GBX 375 ($4.98) price objective on shares of Uniphar in a research report on Wednesday, July 30th.

Uniphar Price Performance

The company has a debt-to-equity ratio of 119.48, a quick ratio of 0.60 and a current ratio of 0.90. The stock has a market cap of £1.04 billion, a PE ratio of 23.26 and a beta of 0.75. The stock's 50-day moving average is GBX 319.16 and its two-hundred day moving average is GBX 258.62.

Uniphar Company Profile

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.